Search - tctmd.com

Displaying 1 - 20 of 122

Sort: Relevancy | Date

PCI Rebounds at 5 Years to Mostly Match CABG: Final FAME 3 Data

News Conference News ACC 2025

PCI Rebounds at 5 Years to Mostly Match CABG: Final FAME 3 Data

March 31, 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

News Conference News ACC 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Michael O'Riordan

March 29, 2025

TARGET BP 1: Alcohol-Based RDN Promises Single Treatment for Resistant BP

News Conference News ACC 2024

TARGET BP 1: Alcohol-Based RDN Promises Single Treatment for Resistant BP

April 16, 2024

Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing

News Conference News ACC 2024

Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing

Michael O'Riordan

April 12, 2024

Compared With Usual Care, Incorporating Inclisiran Early Cuts LDL

News Conference News ACC 2024

Compared With Usual Care, Incorporating Inclisiran Early Cuts LDL

Yael L. Maxwell

April 09, 2024

Another Win for TAVI in Low-to-Intermediate Risk Patients

News Conference News ACC 2024

Another Win for TAVI in Patients at Low-to-Intermediate Risk: DEDICATE-DZHK6

Yael L. Maxwell

April 08, 2024

ULTIMATE-DAPT: Another Boost for Solo Ticagrelor 1 Month After ACS PCI

News Conference News ACC 2024

ULTIMATE-DAPT: Another Boost for Solo Ticagrelor 1 Month After ACS PCI

Yael L. Maxwell

April 07, 2024

EDTA Chelation No Help in Cutting CV Outcomes After MI in Diabetic Patients: TACT2

News Conference News ACC 2024

EDTA Chelation No Help in Cutting CV Outcomes After MI in Diabetic Patients: TACT2

April 07, 2024

Early Empagliflozin Doesn’t Curb HF Hospitalizations, Deaths Post-MI: EMPACT-MI

News Conference News ACC 2024

Early Empagliflozin Doesn’t Curb HF Hospitalizations, Deaths Post-MI: EMPACT-MI

April 06, 2024

What’s Going to Be Hot at ACC 2024

News Opinion Editor's Corner ACC 2024

What’s Going to Be Hot at ACC 2024

April 01, 2024

Most HFrEF Patients Eligible for Quadruple Therapy, but Few Get It

News Conference News ACC 2024

Most HFrEF Patients Eligible for Quadruple Therapy, but Few Get It

Michael O'Riordan

March 27, 2024

‘Causal AI’ May Help Guide Specific Actions to Reduce CVD Risk

News Conference News ACC 2023

‘Causal AI’ May Help Guide Specific Actions to Reduce CVD Risk

March 10, 2023

Short DAPT Noninferior to 1 Year After Ultrathin DES PCI: HOST-IDEA

News Conference News ACC 2023

Short DAPT Noninferior to 1 Year After Ultrathin DES PCI: HOST-IDEA

Yael L. Maxwell

March 09, 2023

AIMI-HF Misses Mark With Advanced Imaging in Ischemic HFrEF Workup

News Conference News ACC 2023

AIMI-HF Misses Mark With Advanced Imaging in Ischemic HFrEF Workup

March 09, 2023

Wearable Device Helps HF Patients Avoid Coming Back to the Hospital: BMAD

News Conference News ACC 2023

Wearable Device Helps HF Patients Avoid Coming Back to the Hospital: BMAD

March 06, 2023

PULSED AF ‘Strengthens the Case’ for Pulsed-Field Ablation in AF

News Conference News ACC 2023

PULSED AF ‘Strengthens the Case’ for Pulsed-Field Ablation in AF

March 06, 2023

BETTER CARE-HF: Embedded EHR Alert Boosts MRA Prescribing in HFrEF

News Conference News ACC 2023

BETTER CARE-HF: Embedded EHR Alert Boosts MRA Prescribing in HFrEF

March 06, 2023

COAPT at 5 Years: MitraClip Still Ahead, but Deaths and Crossovers Cast Shadows

News Conference News ACC 2023

COAPT at 5 Years: MitraClip Still Ahead, but Deaths and Crossovers Cast Shadows

March 05, 2023

On-site Machine Learning-Based FFRCT Feasible, Informative: TARGET

News Conference News ACC 2023

On-site Machine Learning-Based FFRCT Feasible, Informative: TARGET

March 04, 2023

Stable CAD Plaque Morphology Improved by PCSK9 Inhibitors: YELLOW III

News Conference News ACC 2023

Stable CAD Plaque Morphology Improved by PCSK9 Inhibitors: YELLOW III

March 04, 2023

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.